Page 88 - Read Online

Ma et al. Hepatoma Res. 2026;12:43 Page 19 of 22

for the accuracy, integrity, and final content of the manuscript.

Financial support and sponsorship
This work was supported by National Key R&D Program of China (No. 2023YFC2413500), National Natural
Science Foundation of China (82130060, 82072039, 82372067), Jiangsu Provincial Basic Research Program
Natural Science Foundation-Frontier Leading Technology Basic Research Project (BK20232008), Jiangsu
Provincial Medical Innovation Center (CXZX202219), the Natural Science Foundation of Jiangsu Province
(BG2024007), New Round of Xuzhou “Pengcheng Talent Program” - High-level Healthcare Talent
Recruitment and Development Project (Project Number: 2025TD09), the Nanjing Municipal Special Fund
for Health Science and Technology Development (YKK23268), the Nanjing Postdoctoral Research Funding
Project (FTJ-bh-10). The funding sources had no role in the writing of the report or in the decision to submit
the paper for publication.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2026.

REFERENCES

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63. DOI PubMed
2. Zheng RS, Chen R, Han BF, et al. [Cancer incidence and mortality in China, 2022]. Zhonghua Zhong Liu Za Zhi. 2024;46:221-31. DOI
PubMed
3. Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer.
2022;161:108-18. DOI PubMed
4. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol.
2022;76:681-93. DOI PubMed PMC
5. Lanza C, Ascenti V, Amato GV, et al. All you need to know about TACE: a comprehensive review of indications, techniques, efficacy,
limits, and technical advancement. J Clin Med. 2025;14:314. DOI PubMed PMC
6. Chen S, Peng Z, Zhang Y, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma:
abandon or repeat? Radiology 2021;298:680-92. DOI PubMed
7. Sun X, Wei T, Kang T, Zhang Y, Huang G. Meta-analysis of the value of albumin-bilirubin grading on changes in liver function and its
prognostic assessment in patients with hepatocellular carcinoma treated with transhepatic arterial chemoembolization. World J Surg
Oncol. 2025;23:361. DOI PubMed PMC
8. Zhou J, Sun H, Wang Z, et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition).
Liver Cancer. 2025;14:779-835. DOI PubMed PMC
9. Vogel A, Chan SL, Dawson LA, et al. ; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hepatocellular
carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:491-506. DOI PubMed
10. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026
update. J Hepatol. 2026;84:631-54. DOI PubMed
11. Zhu H, Liu R, Jia Z, et al. Transarterial chemoembolization for hepatocellular carcinoma: Treatment algorithm proposed by Chinese
College of Interventionalists (CCI). EngMedicine. 2024;1:100037. DOI
12. Zhong BY, Fan W, Guan JJ, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol
Hepatol. 2025;10:369-86. DOI PubMed